Kolon TissueGene (950160) continued its weak performance on July 20, following a sharp decline on July 16 ahead of the Constitution Day holiday. During intraday trading, the stock temporarily fell below the 60,000 won level before recovering, but with no clear rebound momentum in sight, investor attention is now focused on the stock's future direction.

Looking at July 20's trading, Kolon TissueGene closed at 61,200 won, down 900 won (1.45%) from the previous trading day. During the session, the stock fell to as low as 58,900 won, briefly losing the 60,000 won level, but bargain-hunting buying helped it reclaim that threshold. However, the recent trend remains concerning. On July 16, the stock also recorded a steep decline as losses widened toward the afternoon.

With investor sentiment shrinking amid consecutive weakness, assessments suggest that a new catalyst is needed for the stock to transition into a full-scale rebound phase.

The market environment on July 20 was also unfavorable. The KOSDAQ index saw significantly expanded volatility, with a sell-side trading halt (sell-side circuit breaker) triggered due to a sharp intraday decline. KOSDAQ ultimately closed at 749.64, down 42.20 points (5.32%) from the previous session, reflecting a sharp contraction in investor sentiment.

The market views whether Kolon TissueGene can defend the 60,000 won level in the short term as a key inflection point. The critical question is whether the stock can build a rebound trend based on that price level, or whether weakening support will lead to expanded volatility.

Meanwhile, according to a disclosure on July 20, TG-C failed to demonstrate statistically significant improvement compared to a placebo in the co-primary efficacy evaluation metrics at 12 months (VAS pain score and WOMAC total score). However, the company stated that the 104-week safety analysis showed favorable overall safety and tolerability, with no new safety signals identified. The company also explained that it plans to consult with the U.S. FDA in the future by comprehensively reviewing these results alongside those of another ongoing U.S. Phase 3 clinical trial.

As an investment caution, the company noted that the statistical probability of a clinical trial drug receiving final approval in new drug development is generally known to be around 10%, and that if results during clinical trials and the product approval process fall short of expectations, commercialization plans may be altered or discontinued. Following the related disclosure, Kolon's NXT also hit the lower limit.

Attention is also focused on how this series of issues will affect Kolon TissueGene's stock price movement on July 21.

[※ This article is based on market trends and is not intended to recommend or solicit the purchase or sale of any specific stock. Investment decisions and responsibilities lie with the investor.]